SCHEMBL2651972

SCHEMBL2651972

Cc1nc(NC(=O)/C(=C\c2cccs2)c2ccccc2)sc1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 3/20 0.67
RAB9A P51151 8/20 0.56
NPC1 O15118 6/20 0.56
PKM P14618 2/20 0.56
NPSR1 Q6W5P4 5/20 0.47
ALDH1A1 P00352 3/20 0.47
POLB P06746 2/20 0.47
THRB P10828 1/20 0.47
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
TP53 P04637 1/20 0.46
NFKB1 P19838 1/20 0.46
HTT P42858 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
MCOLN3 Q8TDD5 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651974 1.00 GCK (0.67) GCKRAB9ANPC1PKMNPSR1
SCHEMBL2651389 0.90 GCK (0.55) GCKRAB9ANPC1PKMNPSR1
SCHEMBL2651392 0.90 GCK (0.55) GCKRAB9ANPC1PKMNPSR1
SCHEMBL2653036 0.82 GCK (0.71) GCKRAB9ANPC1PKMNPSR1
SCHEMBL2653033 0.82 GCK (0.71) GCKRAB9ANPC1PKMNPSR1
SCHEMBL2649852 0.81 GCK (1.00) GCKRAB9ANPC1ALDH1A1POLB
SCHEMBL2649857 0.81 GCK (1.00) GCKRAB9ANPC1ALDH1A1POLB
SCHEMBL2651722 0.78 GCK (0.72) GCKRAB9ANPC1NPSR1ALDH1A1
SCHEMBL2651727 0.78 GCK (0.72) GCKRAB9ANPC1NPSR1ALDH1A1
SCHEMBL2653155 0.77 GCK (0.70) GCKRAB9ANPC1PKMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
EP-1594867-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2005-11-16 EP disclosed
US-20040181067-A1 Tri(cyclo) substituted amide compounds OSI PHARMACEUTICALS, INC. 2004-09-16 US disclosed
WO-2004072031-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LIMITED (GB) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181067-A1 Tri(cyclo) substituted amide compounds GPR119, IAPP, SLC5A1 GCK 60/4885RAB9A 3333/4885NPC1 543/4885
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS IAPP, GPR119, SLC5A1 GCK 70/4885RAB9A 3057/4885NPC1 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.